Research
- Institute for Drug Development
- Clinical Studies
Faculty Positions
Physician Directory
Symposia
- San Antonio Breast Cancer Symposium
- New Agents
Education Programs
- CTRC
  - Residency Program
  - Radiological Sciences
  - Dosimetry School
  - Continuing Medical Education
  - Medical Physics Residency
  - Medical Dosimetry Review Courses
- Institute for Drug Development
  - Advanced Oncology/Hematology Drug Development Fellowship Program

Programs / Events

Lung

IMC-A12

Description:

IMC-A12 is a recombinant human antibody that binds to VEGFR-2 blocking the action of VEGF ligand. This approach inhibits the growth of blood vessels that provide the tumor with nutrients and energy. This Phase II study combines IMC-A12 with Paclitaxel and Carboplatin in patients with advanced non-squamous, non-small cell lung cancer.

Type(s) of Cancer: Lung

Study Phase(s): Phase II

Contact: Epp Goodwin at (210) 450-5798

Reolysin+Paclitaxel+Carboplatin

Description: This is a Phase II study where Reolysin is administered intravenously days 1-5 with Paclitaxel and Carboplatin to patients with stage IIIB or IV squamous cell carcinoma of the lung as a first line treatment.